GlassScriptPhysician profile
Matthew N Widmer
NPI 1174866164
$1,352.76
in general payments reported to CMS, 2019-2025
18 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $22.23 · 2021: $13.69 · 2022: $170 · 2023: $265 · 2024: $318 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.06 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.26 | 2022-2025 | Ubrelvy, Qulipta |
| Comsort, INC | $150.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.58 | 2019-2021 | |
| Hydrocision, INC. | $77.01 | 2025 | Tenjet |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Novo Nordisk INC | $40.72 | 2019-2023 | Rybelsus, Ozempic |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Amgen INC. | $36.63 | 2024 | Repatha, Otezla |
| Rock Medical Orthopedics, INC. | $33.50 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $30.78 | 2022-2023 | |
| Horizon Therapeutics Plc | $27.26 | 2020-2022 | |
| Janssen Biotech, INC. | $22.24 | 2023 | Remicade, Stelara, Simponi |
| Glaxosmithkline, LLC. | $20.71 | 2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $20.48 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $15.44 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $15.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.14 | 2019 | |
| Pfizer INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Widmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.